Novel methods of treating hearing loss
US-2024390323-A1 · Nov 28, 2024 · US
Compositions of tryptophol derivatives and 4-ethyl-phenol derivatives, and methods of using same
US12478610B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12478610-B2 |
| Application number | US-202117922790-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 11, 2021 |
| Priority date | May 11, 2020 |
| Publication date | Nov 25, 2025 |
| Grant date | Nov 25, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to a composition including a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and a method of using same, such as for treating a subject in need of modulation of blood coagulation.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method for modulating blood coagulation in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a composition comprising a Tryptophol acetate, and a Tyrosol acetate, in a ratio ranging from 4:1 (w/w) to 1:4 (w/w), thereby modulating blood coagulation in the subject. 2 . The method of claim 1 , wherein said modulating comprises reducing blood coagulation in the subject. 3 . The method of claim 2 , wherein said reducing blood coagulation comprises increasing the clot reaction time, respectively, in said subject, compared to control. 4 . The method of claim 2 , wherein said reducing blood coagulation is in a subject being afflicted with a disease characterized by increased risk for developing blood clots. 5 . The method of claim 4 , wherein said disease comprises diabetes. 6 . The method of claim 1 , wherein said composition is a pharmaceutical composition or a nutraceutical composition. 7 . The method of claim 1 , wherein said Tryptophol acetate, and Tyrosol acetate are present in said composition in a molar ratio) of 1:1 (w/w).
Assignees
Inventors
Classifications
Phenols {(cannabinoids A61K31/658)} · CPC title
with compounds having aromatic groups, e.g. dipivefrine, ibopamine · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
- A61K31/404Primary
Indoles, e.g. pindolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12478610B2 cover?
- The present invention is directed to a composition including a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and a method of using same, such as for treating a subject in need of modulation of blood coagulation.
- Who is the assignee on this patent?
- B G Negev Technologies And Applications Ltd At Ben Gurion Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K31/404. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).